Sonoma Pharmaceuticals, Inc., a global healthcare company in developing and producing stabilized hypochlorous acid (HOCl) products based on its patented Microcyn® technology, unveiled a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP. The product will be supplied by Medline into hospital systems, home healthcare as well as other healthcare channels across the United States.
This initiative between Sonoma with Medline which was initiated in 2024, combines Sonoma's expertise in developing safe as well as effective HOCl-based solutions with Medline's extensive hospital and healthcare distribution network.
The new product provides clinicians with an advanced wound cleansing solution designed to promote healing and reduce infection risk without damaging healthy tissue.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants.
Medline is a healthcare company - a medical supply manufacturer, distributor, and solutions provider focused on improving the overall operating performance of healthcare.
Executive Statement
According to Amy Trombly, CEO of Sonoma Pharmaceuticals, they are very excited for the launch of the new HOCl wound cleanser into hospitals in the United States, which marks a significant milestone in the growth of their U.S. business. The substantial efforts by both Sonoma and Medline to make this possible reflect the value to patients and doctors in bringing their wound care technology to major hospital systems. They are proud to be contributing to improved patient care across the country.
